Reviewing the role of progesterone therapy in endometriosis

Abdul Kadir Abdul Karim; Abdul Karim; Abdul Karim AK; Mohamad Nasir Shafiee; Shafiee MN; Nor Haslinda Abd Aziz; Onn Haji Hashim; Mohd Hashim Omar; Omar MH; Abdul Ghani NA; Nur Azurah Abdul Ghani; Lim PS; Pei Shan Lim; Md Zin RR; Reena Rahayu Md Zin; Norfilza Mohd Mokhtar; Norfilza Mokhtar

doi:10.1080/09513590.2018.1490404

Reviewing the role of progesterone therapy in endometriosis

Abdul Kadir Abdul Karim, Abdul Karim, Abdul Karim AK, Mohamad Nasir Shafiee, Shafiee MN, Nor Haslinda Abd Aziz, Onn Haji Hashim, Mohd Hashim Omar, Omar MH, Abdul Ghani NA, Nur Azurah Abdul Ghani, Lim PS, Pei Shan Lim, Md Zin RR, Reena Rahayu Md Zin, Norfilza Mohd Mokhtar, Norfilza Mokhtar

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2018 · vol. 35(1) , pp. 10–16 · doi:10.1080/09513590.2018.1490404 · PMID:30044157 · W2883698382

Review OA: closed CC0 ⤵ 25 in-corpus citations

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This review consolidates clinical trials examining progestins and their mechanisms for treating endometriosis, highlighting progesterone resistance as a key factor and discussing progesterone receptor modulators as potential therapeutic targets.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is a benign, chronic inflammatory condition characterized by the presence and growth of endometrial implants outside the uterine cavity. The cause of endometriosis is multifactorial. It is due to the diversity of hypothesis and plausibility of hormonal alterations which could play a major role. Evidence has shown that progesterone resistance is a key factor for endometriosis sufferers. Medical therapy can avoid surgical intervention, which may lead to a reduced in ovarian reserve, and its effects of earlier menopause and reduced fecundity. Progesterone receptor isoform has provided new insight as the potential treatment. Progestin, anti-progestin and selective progesterone receptor modulators usage, which target these receptors, could avoid hypo-estrogenic side effects, which can be debilitating. Numerous types of these medications have been used on and off labeled to treat endometriosis with varying success. This review aims to consolidate series of clinical trials using progestins in endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Progesterone Endometriosis Endometriosis Female Female Humans Humans Progesterone Progesterone Treatment Outcome Treatment Outcome

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (66)

Cited by (25)

Source provenance

europepmc: last seen: 2026-10-14T06:08:39.101224+00:00
openalex: last seen: 2026-06-10T17:14:06.276822+00:00
pubmed: last seen: 2026-10-08T21:22:34.444095+00:00
unpaywall: last seen: 2026-10-14T06:23:58.021457+00:00

License: CC0 · commercial use OK

[1] A case report of thoracic endometriosis - A rare cause of haemothorax via openalex

[2] A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis via openalex

[3] Changes in quality of life after hormonal treatment of endometriosis via openalex

[4] Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis via openalex

[5] Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol via openalex

[6] Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis via openalex

[7] Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis via openalex

[8] Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission via openalex

[9] Dienogest for Treatment of Endometriosis in Chinese Women: A Placebo-Controlled, Randomized, Double-Blind Phase 3 Study via openalex

[10] Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis via openalex

[11] Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex

[12] Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial via openalex

[13] Effective post-laparoscopic treatment of endometriosis with dydrogesterone via openalex

[14] Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis via openalex

[15] Effects of long-term postoperative dienogest use for treatment of endometriosis on bone mineral density via openalex

[16] Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis via openalex

[17] Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience via openalex

[18] Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study via openalex

[19] Efficacy of Norethisterone in Patients with Ovarian Endometrioma via openalex

[20] Efficacy of the levonorgestrel-releasing intrauterine device in the treatment of recurrent pelvic pain in multitreated endometriosis via openalex

[21] Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density via openalex

[22] Endometriosis via openalex

[23] Endometriosis: current therapies and new pharmacological developments via openalex

[24] Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis via openalex

[25] Endometriosis: the pathophysiology as an estrogen-dependent disease via openalex

[26] Eutopic endometrium from women with endometriosis shows altered ultrastructure and glycosylation compared to that from healthy controls--a pilot observational study via openalex

[27] Expression of the gamma 2 chain of laminin-332 in eutopic and ectopic endometrium of patients with endometriosis via openalex

[28] Gonadotropin-releasing hormone agonist with add-back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis via openalex

[29] Low-dose add-back therapy during postoperative GnRH agonist treatment via openalex

[30] Oral continuous combined 0.5 mg estradiol valerate and 5 mg dydrogesterone as daily add-back therapy during post-operative GnRH agonist treatment for endometriosis in Chinese women via openalex

[31] Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients via openalex

[32] Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial via openalex

[33] Postoperative Levonorgestrel-Releasing Intrauterine System Insertion After Gonadotropin-Releasing Hormone Agonist Treatment for Preventing Endometriotic Cyst Recurrence: A Prospective Observational Study via openalex

[34] Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence via openalex

[35] Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study via openalex

[36] Progesterone receptor isoform A but not B is expressed in endometriosis via openalex

[37] Progesterone Resistance in Endometriosis Is Modulated by the Altered Expression of MicroRNA-29c and FKBP4 via openalex

[38] Progestins for Symptomatic Endometriosis: Results of Clinical Studies via openalex

[39] Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells via openalex

[40] Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex

[41] Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain via openalex

[42] The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis via openalex

[43] The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up via openalex

[44] The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease via openalex

[45] The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis via openalex

[46] The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis via openalex

[47] Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate via openalex

[48] W1569704074 via openalex

[49] W2994812398 via openalex

[50] W1525342509 via openalex

[51] W2101744447 via openalex

[52] W151949596 via openalex

[53] W2104687197 via openalex

[54] W2101417341 via openalex

[55] W2131027406 via openalex

[56] W2095424038 via openalex

[57] W2077644752 via openalex

[58] W2065223935 via openalex

[59] W2228635764 via openalex

[60] W2041320907 via openalex

[61] W2033143591 via openalex

[62] W2586772905 via openalex

[63] W1990483217 via openalex

[64] W1984784419 via openalex

[65] W1978085719 via openalex

[66] W1969489572 via openalex